2022
Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
Waddell JT, Corbin WR, MacKinnon DP, Leeman RF, DeMartini KS, Fucito LM, Kranzler HR, O’Malley S. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. Alcohol Clinical And Experimental Research 2022, 46: 477-491. PMID: 35076087, PMCID: PMC9679805, DOI: 10.1111/acer.14780.Peer-Reviewed Original ResearchConceptsMedication dosageYoung adultsLight drinkingSubjective responsesSubjective effectsHeavy drinkingPlacebo-controlled studyEffect sizePerson effectsEffective treatmentNaltrexoneDrinking daysNaltrexone efficacySmall effect sizesDrinking levelsCravingDrinkingAdultsLaboratory-based studiesPillsMomentary assessmentEfficacyTreatment conditionsDrinking environmentsDaily diary data
2021
Reward drinking and naltrexone treatment response among young adult heavy drinkers
Roos CR, Bold KW, Witkiewitz K, Leeman RF, DeMartini KS, Fucito LM, Corbin WR, Mann K, Kranzler HR, O'Malley SS. Reward drinking and naltrexone treatment response among young adult heavy drinkers. Addiction 2021, 116: 2360-2371. PMID: 33620746, PMCID: PMC8328878, DOI: 10.1111/add.15453.Peer-Reviewed Original Research
2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trial
2016
Nicotine Replacement Therapy Use Predicts Smoking and Drinking Outcomes among Heavy-Drinking Smokers Calling a Tobacco Quitline
Rojewski AM, Fucito LM, Baldassarri S, Hyland A, Cummings KM, Toll BA. Nicotine Replacement Therapy Use Predicts Smoking and Drinking Outcomes among Heavy-Drinking Smokers Calling a Tobacco Quitline. The Journal Of Smoking Cessation 2016, 12: 99-104. PMID: 35082926, PMCID: PMC8788683, DOI: 10.1017/jsc.2016.12.Peer-Reviewed Original ResearchNicotine replacement therapyHeavy drinking daysDrinking daysNRT useFree nicotine replacement therapyNicotine replacement therapy useHeavy drinking smokersState Smokers' QuitlineTobacco counsellingTherapy useCessation assistanceSmoking statusReplacement therapyTobacco quitlineSmoking abstinenceHazardous drinkersSmokersQuitlineHeavy drinkingSuboptimal useDrinking outcomesAbstinenceDaysCounsellingSignificant barriersLongitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers
DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, O’Malley S. Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2016, 84: 185-190. PMID: 26654213, PMCID: PMC4941818, DOI: 10.1037/ccp0000053.Peer-Reviewed Original ResearchConceptsPercent days abstinentFirst placebo-controlled trialPercent days heavy drinkingHeavy drinkingPlacebo-controlled trialLong-term outcomesHeavy drinking daysYoung adults ages 18Adults ages 18Naltrexone conditionActive medicationPlacebo groupPharmacotherapy trialsAdult heavy drinkersYoung adult heavy drinkersNonsignificant decreaseSignificant benefitsYear posttreatmentDays abstinentDrinking daysMost outcomesSingle interventionHeavy drinkersTreatment improvementAge 18
2015
Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE.
Gueorguieva R, Wu R, Fucito LM, O'Malley SS. Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. Journal Of Studies On Alcohol And Drugs 2015, 76: 935-41. PMID: 26562602, PMCID: PMC4712662, DOI: 10.15288/jsad.2015.76.935.Peer-Reviewed Original ResearchConceptsLong-term outcomesBetter long-term outcomesBetter clinical outcomesDrinking outcomesHeavy drinking daysLogistic regression analysisStrongest predictorLogistic regression modelsPredictors of abstinenceFair classification accuracyPatient characteristicsClinical outcomesTerm outcomesCombined PharmacotherapiesClinical trialsBaseline predictorsTreatment outcomesTreatment phaseOptimizing outcomesDrinking daysBetter outcomesAlcohol Dependence (COMBINE) StudyBehavioral interventionsHeavy drinkingAlternative interventionsReduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. The Journal Of Clinical Psychiatry 2015, 76: e207-13. PMID: 25742208, PMCID: PMC4442987, DOI: 10.4088/jcp.13m08934.Peer-Reviewed Original ResearchConceptsHeavy drinking daysBlood alcohol concentrationPercent days abstinentDrinking daysNumber of drinksYoung adultsDays abstinentPercent heavy drinking daysOutpatient research centerSafety of naltrexonePlacebo-controlled studySerious adverse eventsRisk-benefit ratioPercentage of daysAdverse eventsSecondary outcomesPrimary outcomeFrequency of drinkingOpioid antagonistAdult heavy drinkersAlcohol drinkingClinical trialsEvaluable samplesYoung adult heavy drinkersTreatment period
2011
A preliminary investigation of varenicline for heavy drinking smokers
Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011, 215: 655-663. PMID: 21221531, PMCID: PMC3645986, DOI: 10.1007/s00213-010-2160-9.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersActive medicationPretreatment groupAlcohol cravingHeavy drinkersOpen-label phaseSmoking cessation pharmacotherapyEffects of vareniclineHeavy drinking daysGreater reductionPlacebo leadVarenicline pretreatmentCessation counselingCessation pharmacotherapyAbstinence ratesCigarette smokingVareniclineSmoking changesDrinking daysPotential treatmentSmokingAlcohol dependenceEntire study periodSmokersHeavy drinking